Pioneering diagnostics
E.g., 23/08/2019
E.g., 23/08/2019

Nine-Month Sales Up 5.6% at Constant Exchange Rates

20 October, 2004

Marcy l'Etoile, France - October 20th, 2004. bioMérieux, a global leader in the field of in vitro diagnostics, today announced its sales for the first nine months of 2004.

bioMérieux signs New Agreements with Gen-Probe

07 October, 2004

Marcy l'Etoile, France - October 7th, 2004. bioMérieux receives a $ 1 million license fee for access to its markers for blood clotting disorders. bioMérieux to give Gen-Probe an option for the access to bioMérieux NUCLISENS EASYQ® platform. bioMérieux Gains Access to ribosomal RNA...

Appointment of an Independent Board Member - Composition of Audit and Compensation Committees

01 October, 2004

Marcy l'Etoile, France - October 1st, 2004.

  • bioMérieux announces the nomination of a new independent Board Member, Mr Michel Angé, Vice-Président of APICIL-Prévoyance, to its Board of Directors. This nomination brings the total number of company...

bioMérieux Announces 23% Increase in First-Half 2004 Operating Income and Net Income

01 October, 2004

Marcy l'Etoile, France - October 1st, 2004. bioMérieux, a global leader in the field of in vitro diagnostics, today announces a significant increase in its financial results for the six months ended June 30, 2004.

bioMérieux innovates further in the fight against AIDS

27 September, 2004

Marcy l'Etoile, France - September 27th, 2004. A major player in the field of in vitro diagnostics, bioMérieux confirms its constant commitment to the fight against AIDS with the launch of two new advanced 4th generation tests for HIV screening. VIDAS® HIV DUO ULTRA and VIDAS...

VIDAS® D-Dimer Exclusion™ test from bioMérieux for reliable exclusion of pulmonary embolism and deep vein thrombosis

23 July, 2004

Marcy l'Etoile, France - July 23rd, 2004. bioMérieux announces that its D-dimer assay, VIDAS D-Dimer Exclusion, is now cleared by the U.S. Food and Drug Administration (FDA) to exclude both pulmonary embolism (PE) and deep vein thrombosis (DVT) as a diagnosis in outpatients. VIDAS D-Dimer...

Six month report January - June 2004: Sales - in line with expectations

21 July, 2004

Marcy l'Etoile, France - July 21st, 2004. bioMérieux (Euronext : FR0010096479 – BIM) today announced: During the first six months to June 2004, bioMérieux achieved sales of Euros 461 million - an increase of 3 per cent compared to the same period in 2003. The strength of the Euro,...

bioMérieux laboratories grant license to Eppendorf for One Step RT-PCR technology

13 May, 2004

Marcy l'Etoile, France - May 13, 2004. Eppendorf AG, Germany, and bioMérieux, France, have concluded a non-exclusive licensing agreement for Eppendorf products using bioMérieux's exclusively controlled One Step RT-PCR technology.

Eppendorf receives all the rights for...

VIDAS® D-Dimer Exclusion test from bioMérieux for reliable exclusion of venous thromboembolism

06 May, 2004

Marcy l'Etoile, France - May 6th, 2004. bioMérieux announces that following prospective management studies on its VIDAS D-Dimer test resulting in FDA approval and CE marking, the VIDAS D-Dimer New test has been renamed VIDAS D-Dimer Exclusion™. This name change will more accurately...

bioMérieux and South Africa, united in the fight against AIDS

04 May, 2004

Marcy l'Etoile, France - May 4th, 2004. A major player in the field of infectious disease, bioMérieux, and its exclusive distributor for South Africa, Omnimed, have just won a most important tender for the National Health Laboratory Services of South Africa as regards the fight against the...